NCT06279286 - Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder | Biotech Hunter

Enrollment

312

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Insomnia Disorder

Interventions

DRUG

HS-10506

HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.

DRUG

Placebo

Placebo, placebo tablets matching the HS-10506 tablets

Trial Locations (1)

Xuanwu Hospital Capital Medical University, Beijing